BridgeBio Pharma (BBIO) Assets Average (2018 - 2026)

BridgeBio Pharma has reported Assets Average for 9 years, with the latest figure at $1.2 billion in Q1 2026.

• Quarterly Assets Average rose 28.1% year-over-year to $1.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 billion (up 28.1% YoY) and the FY2025 annual result came in at $927.7 million, up 26.58% from the prior year.
• Assets Average grew to $1.2 billion in Q1 2026 per BBIO's latest filing, from $967.1 million in the prior quarter.
• Over five years, Assets Average peaked at $1.2 billion in Q1 2026 and troughed at $564.7 million in Q2 2023.
• A 5-year average of $804.3 million and a median of $795.5 million in 2022 frame the typical range for Assets Average.
• The sharpest annual moves came in 2023 and 2024: Assets Average plunged 32.59% in 2023, then surged 45.55% in 2024.
• Over 5 years, Assets Average stood at $675.9 million in 2022, then declined by 11.13% to $600.7 million in 2023, then jumped by 31.87% to $792.2 million in 2024, then advanced by 22.09% to $967.1 million in 2025, then climbed by 19.27% to $1.2 billion in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $1.2 billion, $967.1 million, and $1.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.